Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Precision Oncology ProgramOncology Center of Excellence Precision Oncology Program
  
  	
    Share
    Post
    Linkedin

    Email
    Print**Precision in Oncology**

Precision oncology leads to customization of healthcare, with medical decisions, practices and products being tailored to each individual patient with cancer. In oncology drug, biologic, and device development, more precise targeting of a product to an individual’s genomic, proteomic, metabolomic make-up will likely lead to more effective and less toxic anti-cancer therapies.

The Oncology Center of Excellence (OCE), charged with integrating the expertise of the product centers to advance care for patients with cancer, is uniquely situated to develop the methodologies to advance Precision Oncology. The focus of the Precision Oncology Program will be to coordinate and integrate efforts across the centers to:

Educate FDA staff on the state of the science and cutting-edge research in precision oncology.
	Interface with the public and key external stakeholders and educate the public regarding FDA’s role in the advancement of precision oncology.
	Catalyze regulatory science research and development to apply new methodologies to deliver the promise of precision oncology for new and better drugs, diagnostics, and biologics to reduce the burden of cancer.**Companion Diagnostics**

A  companion diagnostic is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product.

Companion diagnostics can:

•    identify patients who are most likely to benefit from a particular therapeutic product,
•    identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product, or
•    monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.

If the diagnostic test is inaccurate, then the treatment decision based on that test may not be optimal.

For the list of cleared or approved companion diagnostic devices, visit List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools).

**Oncology Diagnostic Pilot**

The FDA issued a final guidance, “Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program,” in June 2023, to announce and describe the FDA’s voluntary pilot program for certain CDER-regulated oncology drug products used with certain in vitro diagnostic tests. For additional information on this pilot program, visit the Pilot Program landing page.

                                                                                  Content current as of:
      06/20/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop